In this respect, CX3CL1 may be considered a chemokine suitable for immunoprevention or gene therapy in colorectal cancer, hepatocellular carcinoma, and, more recently, in gastric adenocarcinoma where its expression correlates with induction of both innate and adaptive immunity [88]. The gene discussed is CX3CL1; the disease is hepatocellular carcinoma.